The eye as a window into sickle cell disease morbidity
The eye as a window into sickle cell disease morbidity
批准号:
10271046
负责人:
JING JIN
金额:
$31.86万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-08-01 至 2024-06-30
关键词:
AffectAgeAlzheimer&aposs DiseaseAmericanAreaBlindnessBlood CirculationBlood VesselsBrainBrain Hypoxia-IschemiaBrain InfarctionBrain InjuriesBrain PathologyBrain imagingCerebral InfarctionCerebrovascular DisordersCerebrumCessation of lifeChildChildhoodClinicalClinical DataClinical MarkersComplexComplicationCoronary heart diseaseDNA Sequence AlterationDataDelawareDetectionDiabetes MellitusDiagnosisDiagnosticDiseaseDisease MarkerDisease ProgressionEarly DiagnosisEarly InterventionEarly treatmentErythrocytesEvaluationEventEyeFluorescein AngiographyFunctional disorderFutureGenotypeGoalsGrowthGrowth FactorGuidelinesHealthHematologyHemoglobinopathiesHemorrhageImageImaging TechniquesImaging technologyInheritedInterruptionInterventionInvestigationIschemic Brain InjuryKidney DiseasesKnowledgeLaboratoriesLeadLinkMagnetic Resonance ImagingMethodsModalityModernizationMonitorMorbidity - disease rateMultiple SclerosisNational Eye InstituteNational Institute of Neurological Disorders and StrokeNeuraxisNeurologicObstructionOphthalmic examination and evaluationOphthalmologyOptical Coherence TomographyOrganOutcomePathologicPathologic ProcessesPathologyPatientsPeripheralPopulationQuality of lifeReportingResearchResolutionRetinaRetinal DetachmentRetinal DiseasesRetinal NeovascularizationRetinal Vascular OcclusionRiskSavingsScanningSeverity of illnessSickle CellSickle Cell AnemiaStrokeStructureTechniquesTestingTimeTissuesTreatment EfficacyUnited States National Institutes of HealthUp-RegulationVascular DiseasesVascular ProliferationVisionVisualVitreous Hemorrhageaccurate diagnosishigh riskimprovedinsightinterestneovascularizationnoninvasive diagnosisnovelnovel therapeutic interventionoutcome predictionpreservationpreventretina circulationretinal damageretinal imagingroutine screeningscreeningsickle cell retinopathysicklingstandard of carestroke risktreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Sickle cell disease (SCD) is the most common genetic mutation among the US population, affecting
approximately 100,000 Americans. As a systemic illness, SCD attacks multiple organs including the eyes.
Although SCD can affect nearly all structures in the eye, sickle cell retinopathy (SCR) is the vision threatening
complication with a reported 10% blindness rate. SCR damage often begins in childhood and progresses with
age. Early in SCR, small peripheral retinal vascular occlusions, also known as “retinal stroke”, are typically
asymptomatic. However, as the disease progresses, abnormal blood vessels begin to grow (neovascularization
or proliferative change). Advanced proliferative SCR can lead to intraocular hemorrhage, retinal detachment and
vision loss. Currently, there are no proven methods to prevent SCR, and treatment options are focused on
deterring the progression of proliferative SCR. Prompt diagnosis of SCR is an important step for early treatment,
which can prevent vision loss. The diagnostic strategies focus on visualizing signs of retinal stroke and abnormal
vessel growth. NIH guidelines recommend annual screening for SCR by dilated funduscopic examination of the
eye beginning at age ten, which has low sensitivity. The pathological process of retinal neovascularization is a
complex phenomenon under active investigation. The research proposed in this application, The Eye as a
Window into Sickle Cell Disease Morbidity, will utilize a combination of standard and novel noninvasive
diagnostic modalities to examine retinal circulation and structure changes in children with SCD. Using these
techniques will improve our ability to accurately diagnose and monitor SCR in children and provide a better
understanding of the mechanism of the disease. Furthermore, the value of sensitive and specific assessments
of ocular changes in SCD is not limited to saving vision. For many neurologic conditions and systemic illnesses,
ocular findings aid in both diagnosis and monitoring of overall disease progression. Thus, findings from the
proposed ophthalmologic examinations may elucidate a link between retinal damage and damage to other at-
risk organs, especially the brain in SCD. Through this study, we will refine our ability to predict progression,
assess therapeutic efficacy, develop more effective monitoring guidelines and initiate early interventions.
Correlating retinal findings with clinical data may provide insight into other vascular complications of SCD, such
as cerebrovascular disease. The long-term goal of this study is to enhance early detection of SCR and develop
treatment strategies to slow the progression of SCR toward proliferative retinopathy and blindness, lowering the
societal burden of SCR and improving the quality of life for these patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The eye as a window into sickle cell disease morbidity
-
批准号:10664932
-
项目类别:
-
资助金额:$23.69万
-
财政年份:2014
-
负责人:JING JIN
-
依托单位:
The eye as a window into sickle cell disease morbidity
-
批准号:10463775
-
项目类别:
-
资助金额:$23.69万
-
财政年份:2014
-
负责人:JING JIN
-
依托单位:
BIOCHEMISTRY OF HUMAN OPSIN IN TRANSGENIC MOUSE RETINAS
-
批准号:2160539
-
项目类别:
-
资助金额:$3.53万
-
财政年份:1996
-
负责人:JING JIN
-
依托单位:
BIOCHEMISTRY OF HUMAN OPSIN IN TRANSGENIC MOUSE RETINAS
-
批准号:2160537
-
项目类别:
-
资助金额:$3.53万
-
财政年份:1995
-
负责人:JING JIN
-
依托单位:
BIOCHEMISTRY OF HUMAN OPSIN IN TRANSGENIC MOUSE RETINAS
-
批准号:2160538
-
项目类别:
-
资助金额:$3.53万
-
财政年份:1995
-
负责人:JING JIN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: